SUZHOU, China, and ROCKVILLE, MD, March 23, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the global Phase Ib/II clinical study of APG-2575, a Bcl-2 selective inhibitor, as a single agent or in combination for Read More ›

SUZHOU, China, and ROCKVILLE, MD, March 9, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that two clinical studies of APG-2575, a novel Bcl-2 selective inhibitor being developed by Ascentage Pharma, have recently received clearances from Read More ›

SUZHOU, China and ROCKVILLE, MD., February 24, 2020 — Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has received approval from Center of Drug Evaluation (CDE), China NMPA, for the Phase Ib/II clinical trial of APG-1387, Read More ›

SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2019 /PRNewswire/ – Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the updated results from the Phase I study of the company’s novel investigational drug HQP1351 were reported in an oral presentation at the 61st American Society of Read More ›

SUZHOU, China and ROCKVILLE, Md., Nov. 20, 2019 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies, announced that the groundbreaking ceremony for the Company’s global headquarters, R&D center, and manufacturing facility took place today at the Suzhou Industrial Park (SIP). The ceremony marks another milestone in Ascentage Pharma’s path of Read More ›

SUZHOU, China and ROCKVILLE, MD., November 14, 2019 — Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the updated preliminary results from a Phase I clinical trial on the company’s novel investigational drug HQP1351 has been accepted for oral Read More ›

Oct 28, 2019, is an unforgettable day for every employee working at Ascentage Pharma. A new history was made when the bell rang at 9:30 a.m. Marking a major milestone in the history of Ascentage, the company was officially listed on the Hong Kong Stock Exchange after the 10-year journey of persistent innovation. For those Read More ›

SUZHOU, China and ROCKVILLE, Md., July 21, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company was notified by the U.S. Food & Drug Administration (FDA) on the clearance of the Investigational New Drug (IND) application which Read More ›

SUZHOU, China and ROCKVILLE, Md., July 14, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company recently dosed the first patient successfully in a Phase I clinical trial of APG-2575, a novel Bcl-2 selective inhibitor, for the Read More ›

SUZHOU, China and Chicago, June 3, 2019 — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company presented new data of two apoptosis-targeted drug candidates APG-115 (a novel MDM2-p53 inhibitor) and APG-1387 (a novel IAP inhibitor) at the 55th Read More ›